BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
Pfizer and Valneva's Lyme disease vaccine showed 73% efficacy in Phase 3 but missed its primary statistical endpoint due to lower-than-expected case counts. Both companies plan to file for approval anyway. Valneva stock cratered over 35%.
Apogee Therapeutics (APGE) reported 52-week maintenance data for zumilokibart in moderate-to-severe eczema, showing 85% of patients maintained response with dosing just twice a year. That directly challenges Dupixent's every-two-week regimen.
Insmed (INSM) posted positive Phase 3b ENCORE results for ARIKAYCE in newly diagnosed MAC lung disease, fulfilling an FDA post-marketing requirement and setting up a supplemental approval filing in H2 2026.
⚡ Executive Takeaway
Monday delivered a study in contrasts. Pfizer and Valneva's Lyme disease vaccine showed meaningful clinical efficacy at 73%, but a lower-than-expected case count during the study period meant it couldn't clear the prespecified statistical confidence interval. The companies are filing for approval regardless, and the regulatory question now becomes whether the FDA treats this as a math problem or a science problem. The vaccine works; the trial just didn't accrue enough events to prove it with the statistical rigor regulators typically require.
In immunology, Apogee quietly dropped one of the most commercially compelling data packages of the month. Zumilokibart maintained eczema responses for a full year with injections every three to six months. In a world where Dupixent patients inject every two weeks and Ebglyss patients inject monthly, a twice-a-year option rewrites the convenience equation entirely. Meanwhile, Insmed checked a critical box for ARIKAYCE with positive ENCORE data in frontline MAC lung disease, clearing the path to expand from refractory to newly diagnosed patients. 👉 Read Full Analysis
🔮 What To Watch
Pfizer/Valneva Regulatory Strategy: The companies plan to file for U.S. and EU approval despite the primary endpoint miss. Watch for an FDA advisory committee meeting, which is highly likely given the statistical shortfall. Analysts note that HHS Secretary Kennedy has highlighted the need for Lyme treatments, which could translate into a sympathetic regulatory reception.
Apogee Phase 3 Timing: Zumilokibart's APEX Phase 2 data is being presented at the AAD annual meeting. The Phase 3 trial design and timeline will be the next major catalyst to watch.
Rocket Pharma (Friday, March 28): Kresladi PDUFA for LAD-I gene therapy is just days away.
ACC.26 (March 28-30): The American College of Cardiology meeting in New Orleans kicks off this weekend.
Orforglipron (April 10): Lilly's oral GLP-1 target action date approaches.
🚀 Today's Top Story
Pfizer's Lyme Vaccine Works. The Trial Didn't Prove It Enough.
What Happened: Pfizer (PFE) and Valneva (VALN) reported results from the Phase 3 VALOR trial of their six-valent Lyme disease vaccine (VLA15) in approximately 9,400 individuals aged 5 and older.
The Data: The vaccine demonstrated 73.2% efficacy at preventing Lyme disease 28 days after the fourth dose. However, because fewer Lyme cases than expected accrued during the study period, the lower bound of the 95% confidence interval was 15.8%—falling below the required 20% statistical threshold. Therefore, the primary endpoint was not met.
The Context: This trial has a rocky history. In 2023, Pfizer and Valneva had to drop roughly half of the enrolled participants (from ~18,000 to ~9,400) after good clinical practice violations were discovered at sites run by a third-party operator. That reduction directly contributed to the underpowered statistical result. No safety concerns were observed.
The Regulatory Gamble: Both companies are planning to file for approval anyway, pointing to a second prespecified analysis where efficacy was 74.8% one day after the fourth dose, with the confidence interval just clearing the 20% threshold. Pfizer's Chief Vaccines Officer called the 70%+ efficacy "highly encouraging."
Executive Impact: Valneva stock dropped over 35% on Monday; Pfizer was largely unaffected. The regulatory path is genuinely uncertain. While the current administration has expressed a clear interest in addressing Lyme disease, the commercial reality remains difficult. RBC estimates peak annual sales at only ~$525 million, noting historical demand for a Lyme vaccine has been "tepid at best." (GSK famously withdrew Lymerix in 2002 due to poor sales). Moderna also has two competing mRNA-based Lyme candidates in mid-stage testing.
🔬 Clinical & Research Updates
Apogee's Twice-a-Year Eczema Shot Rewrites the Convenience Equation
What Happened: Apogee Therapeutics (APGE) reported 52-week maintenance data from Part A of the Phase 2 APEX trial evaluating zumilokibart (APG777), a potential best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis.
The Numbers: Among Week 16 responders, 75% of patients dosed every three months maintained EASI-75 response at one year. Even more striking: 85% of patients dosed every six months (just two injections per year) maintained the same level of response.
Executive Impact: This is the exact dosing convenience story the massive immunology market has been waiting for. Dupixent requires injections every two weeks; Ebglyss is monthly. A twice-a-year option with biologic-caliber maintenance efficacy fundamentally changes the treatment calculus for patients and prescribers. For Sanofi/Regeneron (Dupixent) and Lilly (Ebglyss), this is a long-term competitive threat that just became highly credible.
Insmed Clears a Critical Post-Marketing Hurdle for ARIKAYCE
What Happened: Insmed (INSM) reported positive topline results from the Phase 3b ENCORE study of ARIKAYCE in patients with newly diagnosed or recurrent MAC lung disease who had not previously received antibiotics.
The Data: The trial met its primary endpoint, showing a statistically significant improvement in respiratory symptom scores at Month 13. All secondary endpoints were also met.
Executive Impact: This data fulfills an FDA post-marketing requirement that was a strict condition of ARIKAYCE's original accelerated approval for refractory MAC lung disease. Insmed plans to file for supplemental U.S. approval and Japanese label expansion in H2 2026. ARIKAYCE generated $434M in 2025 revenue and is guided for $450-$470M in 2026; expanding into frontline MAC could meaningfully steepen that revenue trajectory.
🔒 BioMed Nexus Pro — Institutional Intelligence Brief
In Today's Pro Brief:
🧠 The Lyme Vaccine Regulatory Math: Why filing after a primary endpoint miss is not unprecedented, and what FDA advisory committee dynamics could look like under current leadership.
⚖️ Apogee's Threat to the IL-13 Franchise: Where zumilokibart fits vs. Dupixent and Ebglyss on efficacy, dosing, and market positioning.
🧮 Insmed's Dual-Asset Story: What frontline MAC approval means for the broader brensocatib launch narrative.
Selective 2026 sponsorship placements are available
Reply directly to discuss a partnership or submit an inquiry here